HC Wainwright Weighs in on Sanara MedTech Q1 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI) – HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Sanara MedTech in a note issued to investors on Monday, August 18th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.22) per share for the quarter. HC Wainwright has a “Buy” rating and a $54.00 price target on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech’s Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.21) EPS and Q4 2026 earnings at ($0.20) EPS.

Sanara MedTech Stock Performance

SMTI stock opened at $30.86 on Tuesday. The company has a quick ratio of 2.03, a current ratio of 2.26 and a debt-to-equity ratio of 1.25. The business’s fifty day simple moving average is $27.74 and its two-hundred day simple moving average is $30.38. Sanara MedTech has a twelve month low of $23.53 and a twelve month high of $39.08. The firm has a market cap of $274.65 million, a price-to-earnings ratio of -26.60 and a beta of 1.26.

Sanara MedTech (NASDAQ:SMTI) last released its earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.10. Sanara MedTech had a negative return on equity of 26.43% and a negative net margin of 10.22%.The business had revenue of $25.83 million for the quarter, compared to analyst estimates of $25.15 million.

Institutional Trading of Sanara MedTech

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC increased its stake in Sanara MedTech by 63,100.0% in the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock worth $89,000 after purchasing an additional 3,155 shares during the period. Marshall Wace LLP increased its stake in Sanara MedTech by 144.3% in the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after purchasing an additional 42,237 shares during the period. Hsbc Holdings PLC purchased a new stake in Sanara MedTech in the second quarter worth $382,000. Stephens Inc. AR increased its stake in Sanara MedTech by 18.0% in the second quarter. Stephens Inc. AR now owns 12,794 shares of the company’s stock worth $363,000 after purchasing an additional 1,952 shares during the period. Finally, Rhumbline Advisers increased its stake in Sanara MedTech by 14.9% in the first quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock worth $115,000 after purchasing an additional 483 shares during the period. Hedge funds and other institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.